<div id="readability-page-1"><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) issued its earnings results on Thursday. The company reported $1.14 EPS for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02), FiscalAI reports. The business had revenue of $283.44 million during the quarter, compared to analysts' expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. During the same period in the prior year, the business posted $1.22 EPS. The business's revenue was down 2.4% on a year-over-year basis.  Prestige Consumer Healthcare updated its FY 2026 guidance to 4.540-4.540 EPS.</p><p>Here are the key takeaways from Prestige Consumer Healthcare's conference call:</p><ul>   <li><span></span><strong>Clear Eyes</strong> supply is improving sequentially and management expects further progress in Q4 and through calendar 2026 after acquiring <strong>Pillar Five</strong> and installing a new <strong>high-speed line</strong>, which should enable internal production, SKU expansion and renewed marketing support.</li>   <li><span></span>Q3 revenue of <strong>$283.4 million</strong> declined ~2.4% YoY (2.2% ex-FX) and adjusted EPS slipped to <strong>$1.14</strong>, driven primarily by Clear Eyes supply constraints and category softness in analgesics and cough &amp; cold.</li>   <li><span></span>Strong cash generation (YTD free cash flow of <strong>$208.8 million</strong>, +12.9%) underpins disciplined capital allocation: the company closed the ~<strong>$110 million</strong> Pillar Five deal and repurchased &gt;<strong>$150 million</strong> of shares (~5% of outstanding), while maintaining net debt of ~<strong>$1 billion</strong> (leverage ~2.6x).</li>   <li><span></span>Management narrowed fiscal 2026 guidance to about <strong>$1.1 billion</strong> in revenue and ~<strong>$4.54</strong> adjusted EPS, expects Q4 adjusted gross margin ~57%, A&amp;M just under 14% of sales and full-year G&amp;A just over 10%, and will provide more 2027 detail on the May call.</li> </ul><h2>Prestige Consumer Healthcare Stock Down 3.3%</h2><p>Shares of NYSE:PBH traded down $2.18 during trading on Thursday, hitting $64.85. 452,612 shares of the company were exchanged, compared to its average volume of 377,745. The stock has a market capitalization of $3.12 billion, a P/E ratio of 16.14, a PEG ratio of 2.02 and a beta of 0.43. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The firm's 50 day moving average price is $62.94 and its 200-day moving average price is $64.12. </p><h2>Analyst Ratings Changes</h2><p>Several research analysts have weighed in on PBH shares. Jefferies Financial Group cut their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a &#34;hold&#34; rating on the stock in a research report on Friday, January 30th. Zacks Research raised shares of Prestige Consumer Healthcare from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday, November 10th. Oppenheimer reduced their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an &#34;outperform&#34; rating for the company in a report on Tuesday, October 21st. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings  reiterated a &#34;hold (c)&#34; rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and four have assigned  a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $84.50.</p><p><b>Read Our Latest Analysis on PBH</b></p><h2>Insiders Place Their Bets</h2><p>In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the firm's stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.40% of the stock is owned by insiders. </p><h2>Hedge Funds Weigh In On Prestige Consumer Healthcare</h2><p>Several large investors have recently modified their holdings of the business. Danske Bank A S bought a new stake in shares of  Prestige Consumer Healthcare in the third quarter worth $37,000.  Brown Brothers Harriman &amp; Co. purchased a new stake in  Prestige Consumer Healthcare in the third quarter valued at $44,000.  Geneos Wealth Management Inc. increased its stake in  Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares in the last quarter.  CIBC Private Wealth Group LLC raised its position in shares of  Prestige Consumer Healthcare by 142.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company's stock worth $69,000 after buying an additional 647 shares during the period.  Finally, State of Wyoming bought a new position in shares of  Prestige Consumer Healthcare in the 2nd quarter worth about $97,000. Hedge funds and other institutional investors own  99.95% of the company's stock. </p><h2>About Prestige Consumer Healthcare</h2> (Get Free Report)<p>Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.  </p><p>Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Prestige Consumer Healthcare</li><li>The day the gold market broke</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Your Bank Account Is No Longer Safe</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Prestige Consumer Healthcare (NYSE:PBH) reported Q3 earnings of $1.14 EPS, missing estimates by $0.02. Revenue was $283.44 million, below expectations of $286.93 million, marking a 2.4% decline year-over-year. The company updated its FY 2026 guidance to approximately $4.54 EPS. Shares fell 3.3% to $64.85. Analysts have mixed ratings, with a moderate buy consensus and an average target price of $84.50. Insiders hold 1.40% of the stock, and recent transactions include VP Jeffrey Zerillo selling shares valued at $43,140.</p>

Prestige Consumer Healthcare (NYSE:PBH) Releases Earnings Results, Misses Expectations By $0.02 EPS